Загрузка...
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summar...
Сохранить в:
| Опубликовано в: : | J Hematol Oncol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4558758/ https://ncbi.nlm.nih.gov/pubmed/26337639 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0195-4 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|